March 8, 2019, Endocrine Today 

Adults with hepatitis C who are treated with direct-acting antiviral therapy are less likely to develop diabetes than those who are treated with pegylated interferon/ribavirin or untreated, according to findings presented at the Conference on Retroviruses and Opportunistic Infections 2019 in Seattle. 

Read more.